Phase Ib Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma

Trial Profile

Phase Ib Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs CVA 21 (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms MITCI
  • Sponsors Viralytics
  • Most Recent Events

    • 09 Aug 2017 Planned number of patients changed from 60 to 59.
    • 23 Jul 2017 Planned number of patients changed from 26 to 60.
    • 23 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top